Dr Reddy's Q4 preview: US sales, Revlimid contribution to deliver another steady quarter
While earnings for Dr Reddy's is expected to remain strong in Q4, an uptick in R&D investments and new intitative may cap the drugmaker's margin expansion.
Stay updated with breaking news from Axis Securities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
While earnings for Dr Reddy's is expected to remain strong in Q4, an uptick in R&D investments and new intitative may cap the drugmaker's margin expansion.
Share market: Friday's market fall came ahead of the release of the US non-farm payroll data. Investors booked profit and there was a degree of caution, said Vinod Nair, Head of Research, Geojit Financial Services.
49 companies, including Titan and Adani Green, to reveal Q4 results. Titan foresees 18% revenue growth and 13% net profit rise. Watch out for updates from Britannia, MRF, Tata Tech, and other key players.
The metals market has seen a strong performance driven by positive PMI data from China and solid US economic fundamentals, leading to higher commodity prices, especially for base metals. Hindalco and Vedanta comparison can help identify better long-term investment opportunities.
Morgan Stanley, Motilal Oswal Financial Services, Axis Securities, and Nuvama have revised their price targets upward for Federal Bank's shares.